Inogen Inc (NASDAQ:INGN) – Investment analysts at Piper Jaffray Companies reduced their FY2018 earnings per share (EPS) estimates for Inogen in a research note issued on Wednesday, November 7th. Piper Jaffray Companies analyst J. Mckim now anticipates that the medical technology company will post earnings of $2.07 per share for the year, down from their prior forecast of $2.12. Piper Jaffray Companies currently has a “Overweight” rating and a $290.00 target price on the stock. Piper Jaffray Companies also issued estimates for Inogen’s Q4 2018 earnings at $0.22 EPS, Q1 2019 earnings at $0.36 EPS, Q4 2019 earnings at $0.34 EPS and FY2020 earnings at $2.19 EPS.
INGN has been the subject of a number of other research reports. Zacks Investment Research raised shares of Inogen from a “hold” rating to a “buy” rating and set a $262.00 target price for the company in a research note on Wednesday, August 22nd. BidaskClub cut shares of Inogen from a “buy” rating to a “hold” rating in a research note on Thursday, October 4th. Needham & Company LLC lifted their target price on shares of Inogen from $215.00 to $254.00 and gave the company a “strong-buy” rating in a research note on Wednesday, August 8th. Finally, ValuEngine cut shares of Inogen from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 1st. One analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $244.67.
Inogen (NASDAQ:INGN) last posted its quarterly earnings results on Tuesday, November 6th. The medical technology company reported $0.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.52 by $0.21. The business had revenue of $95.29 million during the quarter, compared to analyst estimates of $90.94 million. Inogen had a net margin of 12.28% and a return on equity of 19.76%. The company’s revenue was up 38.0% on a year-over-year basis. During the same period in the prior year, the business posted $0.33 earnings per share.
Several hedge funds have recently made changes to their positions in INGN. Zacks Investment Management lifted its stake in Inogen by 1.6% during the second quarter. Zacks Investment Management now owns 17,033 shares of the medical technology company’s stock worth $3,174,000 after purchasing an additional 261 shares during the last quarter. Fuller & Thaler Asset Management Inc. increased its holdings in shares of Inogen by 0.4% during the second quarter. Fuller & Thaler Asset Management Inc. now owns 72,381 shares of the medical technology company’s stock valued at $13,487,000 after purchasing an additional 291 shares during the period. Xact Kapitalforvaltning AB grew its holdings in Inogen by 12.2% during the second quarter. Xact Kapitalforvaltning AB now owns 2,765 shares of the medical technology company’s stock worth $515,000 after acquiring an additional 300 shares during the period. Advisory Services Network LLC grew its holdings in Inogen by 162.5% during the third quarter. Advisory Services Network LLC now owns 525 shares of the medical technology company’s stock worth $128,000 after acquiring an additional 325 shares during the period. Finally, Piedmont Investment Advisors LLC grew its holdings in Inogen by 9.8% during the second quarter. Piedmont Investment Advisors LLC now owns 4,059 shares of the medical technology company’s stock worth $756,000 after acquiring an additional 361 shares during the period. Institutional investors and hedge funds own 96.67% of the company’s stock.
In related news, Director Raymond Huggenberger sold 10,500 shares of the business’s stock in a transaction dated Wednesday, August 15th. The shares were sold at an average price of $228.63, for a total value of $2,400,615.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Brenton Taylor sold 5,000 shares of the business’s stock in a transaction dated Tuesday, September 4th. The stock was sold at an average price of $259.42, for a total transaction of $1,297,100.00. The disclosure for this sale can be found here. Insiders sold a total of 46,000 shares of company stock worth $11,098,610 over the last three months. 5.29% of the stock is currently owned by corporate insiders.
Inogen Company Profile
Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Recommended Story: Understanding Market Liquidity
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.